NBL-015
- Generic Name
- NBL-015
- Drug Type
- Biotech
Evaluation of the Safety and Efficacy of NBL-015 in Patients With Advanced Solid Tumors
- First Posted Date
- 2021-12-10
- Last Posted Date
- 2022-01-03
- Lead Sponsor
- NovaRock Biotherapeutics, Ltd
- Target Recruit Count
- 410
- Registration Number
- NCT05153096
- Locations
- 🇨🇳
Zhongshan Hospital affiliated to Fudan University, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath